Canada markets open in 8 hours 30 minutes

Summit Hotel Properties, Inc. (INN-PE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
20.63-0.24 (-1.15%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close20.87
Open20.75
Bid20.42 x 800
Ask22.90 x 1800
Day's Range20.63 - 20.75
52 Week Range18.38 - 26.98
Volume1,441
Avg. Volume9,060
Market Cap991.162M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateN/A
Forward Dividend & Yield1.56 (7.39%)
Ex-Dividend DateAug 16, 2022
1y Target EstN/A
  • Newsfile

    Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

    6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.Six dogs suffering from osteoarthriti

  • Newsfile

    Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

    First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system

  • Newsfile

    Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent ...